Tasigna (nilotinib) — United Healthcare
Myeloid/Lymphoid Neoplasms with Eosinophilia and Tyrosine Kinase Fusion Genes
Initial criteria
- Diagnosis of myeloid, lymphoid or mixed lineage neoplasms with eosinophilia and ABL1 rearrangement
- AND
- Neoplasm is in blast or chronic phase
Reauthorization criteria
- Patient does not show evidence of progressive disease while on Tasigna therapy
Approval duration
12 months